Purple Biotech shareholders approve all AGM items
Rhea-AI Filing Summary
PURPLE BIOTECH LTD. (PPBT) reports that all proposals presented at its Annual General Meeting of Shareholders, held on September 8, 2026 in Rehovot, Israel, were approved by the required shareholder majorities in accordance with Israeli Companies Law and the company’s articles of association.
The company also states that this report on Form 6-K, including its exhibits, is incorporated by reference into multiple previously filed registration statements on Forms S-8 and F-3, so it becomes part of those registration statements from the submission date.
Positive
- None.
Negative
- None.
Key Terms
Annual General Meeting of Shareholders, Israeli Companies Law, 5759-1999, incorporated by reference, Registration Statement on Form F-3, +1 more
5 terms
Israeli Companies Law, 5759-1999 regulatory
"approved by the requisite vote of the Company’s shareholders in accordance with the Israeli Companies Law, 5759-1999"
incorporated by reference regulatory
"is hereby incorporated by reference into each of the Registrant’s Registration Statement"
Registration Statement on Form F-3 financial
"the Registrant’s Registration Statement on Form F-3, as amended, originally filed"
A registration statement on Form F-3 is a streamlined filing used by eligible foreign companies to register securities for sale in the U.S., often as a “shelf” that lets them offer shares quickly when market conditions are right. For investors it matters because it signals that the company can raise capital on short notice—potentially increasing liquidity but also the risk of share dilution if new stock is issued—similar to a company keeping a pre-approved credit line ready to use.
Registration Statement on Form S-8 financial
"the Registrant’s Registration Statement on Form S-8 filed with the Securities"
A registration statement on Form S-8 is the U.S. Securities and Exchange Commission filing companies use to register shares they intend to grant to employees, directors, consultants or benefit plans under stock compensation programs. It matters to investors because it signals potential issuance of new shares tied to pay and incentives, which can increase the total shares outstanding — like adding more slices to a pie — reducing each existing share’s ownership and potentially affecting earnings per share and stock value.
FAQ
What did PURPLE BIOTECH LTD. (PPBT) announce in this Form 6-K?
The company announced that all proposals at its Annual General Meeting of Shareholders held on September 8, 2026 were approved by the requisite shareholder vote under Israeli Companies Law and its articles of association.
When did PURPLE BIOTECH LTD. (PPBT) hold its 2026 Annual General Meeting?
Purple Biotech Ltd. held its 2026 Annual General Meeting of Shareholders on September 8, 2026 at the company’s offices in Rehovot, Israel.
How does this Form 6-K affect PPBT’s existing registration statements?
Purple Biotech Ltd. states that this Form 6-K, including all exhibits, is incorporated by reference into multiple existing registration statements on Forms S-8 and F-3, making it part of those filings from the date of submission.
Which SEC forms are mentioned as incorporating this PPBT Form 6-K by reference?
The company lists several registration statements on Form S-8 and Form F-3, including file numbers 333-211478, 333-218538, 333-230584, 333-233795, 333-238229, 333-238481, 333-239807, 333-233793, 333-264107, 333-268710 and 333-270769.
AI-generated analysis. How Rhea-AI works. Not financial advice.
